Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study

Meng-Rui Lee1,2,5, Kai-Lun Yu1,2, Hung-Yang Kuo1,3, Tsung-Hao Liu1,3, Jen-Chung Ko1,2, Jaw-Shiun Tsai4 & Jann-Yuan Wang2

The effects of cardiopulmonary resuscitation (CPR) on patients with advanced cancer remain to be elucidated. We identified a cohort of patients with stage-IV cancer who received in-hospital CPR from the Taiwan Cancer Registry and National Health Insurance claims database, along with a matched cohort without cancer who also received in-hospital CPR. The main outcomes were post-discharge survival and in-hospital mortality. In total, 3,446 stage-IV cancer patients who underwent in-hospital CPR after cancer diagnosis were identified during January 2009–June 2014. A vast majority of the patients did not survive to discharge (n = 2,854, 82.8%). The median post-discharge survival was 22 days; 10.1% (n = 60; 1.7% of all patients) of the hospital survivors received anticancer therapy after discharge. We created 1:1 age–, sex–, Charlson comorbidity index (CCI)–, and year of CPR–matched noncancer and stage-IV cancer cohorts (n = 3,425 in both; in-hospital mortality rate = 82.1% and 82.8%, respectively). Regression analysis showed that the stage-IV cancer cohort had shorter post-discharge survival than did the noncancer cohort. The outcome of patients with advanced cancer was poor. Even among the survivors, post-discharge survival was short, with only few patients receiving further anticancer therapy.

Performing cardiopulmonary resuscitation (CPR) on patients with advanced cancer is always a clinical dilemma for clinicians, patients, and their caregivers1,2. CPR, if no benefit, causes suffering for patients and psychological trauma for their loved ones. Studies conducted more than a decade ago have indicated that CPR outcome is generally dismal among patients with cancer3,4. Even if spontaneous circulation returns, only a small proportion of these patients survive to discharge1. In one meta-analysis, metastatic cancer patients receiving in-hospital CPR had only a 5.6% chance of survival to discharge4. Nevertheless, a recent multicentre study in France reported a 14% 6-month survival rate among cancer patients with cardiac arrest who were admitted to an intensive care unit (ICU)5. In another study, only 5.8% of cancer patients who received CPR during their ICU stay left the hospital alive6. The conflicting results obtained by these studies represent a crucial topic worthy of discussion. Although most physicians would agree that cancer patients receiving CPR have a poor prognosis, whether the survival rate of cancer patients receiving CPR changes over time, namely due to improvements in critical and cancer care, remains unclear. Updated epidemiological studies, especially population-based studies, are best placed to answer this question.

Several clinical questions also remain to be answered. First, the clinical course of hospital survivors has not been investigated thoroughly. Little evidence on whether hospital survivors can tolerate further anticancer therapy has been gathered. Moreover, a comparison between the outcomes for cancer and noncancer patients receiving CPR is required. Patients with cancer receiving CPR are generally considered to have poorer outcomes than those without cancer7. The answers to the aforementioned research questions would have an impact on medical

1Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan. 2Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 3Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 4Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan. 5Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. Correspondence and requests for materials should be addressed to J.-Y.W. (email: jywang@ntu.edu.tw)
resource allocation and provide implications for healthcare policymaking. Furthermore, such findings could guide patients and family caregivers in making CPR and do-not-resuscitate (DNR) decisions.

Therefore, we conducted this study to investigate the outcome and prognostic factors in stage-IV cancer patients who received CPR in Taiwan during 2009–2014. To this end, we created a population-based cohort of stage IV cancer patients receiving in-hospital CPR in Taiwan. Also, to provide a general and comparable clinical picture of stage IV cancer patients receiving CPR, we created a matched non-cancer cohort who also received CPR, which was much more commonly encountered in clinical practice, to contrast with the outcome of cancer patients.

Materials and Methods

Ethics statement. The Institutional Review Board of National Taiwan University Hospital Hsin–Chu Branch approved this study (NTUH-HC REC: 105-040-E) and waived the need for informed consent because the data utilised in this retrospective study were deidentified.

Participants and definition. We conducted this study by linking Taiwan National Health Insurance (NHI) claims data, mortality data from the Department of Statistics, and Taiwan Cancer Registry data. The NHI claims data in Taiwan have been previously described4–10. In brief, a compulsory universal NHI programme has been implemented by the Bureau of NHI (currently the NHI Administration [NHIA]) since 1995. This programme covers more than 98% of the total Taiwan population (23 million residents). As a single-payer health insurance system, the NHI database administered by the NHIA provides a population-based research platform for epidemiology studies8–10.

Launched in 1979, the Taiwan Cancer Registry is a prospective population-based cancer data collection platform. In the registry, initial-diagnosis TNM staging according to the American Joint Committee on Cancer staging edition is available in a long-form database, which contains data on more than 90% of all cancer patients in Taiwan11. Researchers can follow cancer patients from their initial diagnosis and treatment course to end of life through linkage between the Taiwan Cancer Registry, NHI claims data, and mortality data.

We first identified patients with incident stage-IV cancer from the Taiwan Cancer Registry; patients with initial diagnoses between 2009 and June 2014 were considered. Patients were included if they received in-hospital CPR after their cancer diagnosis. The hospitalisation course of first in-hospital CPR episode was considered the index hospitalisation. The exclusion criteria were (1) receipt of CPR before stage-IV cancer diagnosis and (2) age at diagnosis < 20 years. The cohort entry date was defined as the admission day of the index hospitalisation. We also identified all patients in Taiwan NHI claims database who received in-hospital CPR between January 2009 and June 2014. The exclusion of patients with cancer was achieved by excluding cancer records in the Taiwan Cancer Registry or the presence of cancer diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM code: 140-208) in any one of five hospitalisation or three outpatient visit diagnosis codes.

For comparing CPR outcome between patients with stage IV cancer and without any cancer, we also 1:1 matched the stage IV cancer group with a noncancer patient group.

Definition and data collection. CPR was identified using the procedure code for payment (47029C). In Taiwan, the NHI payment when CPR is performed is calculated in units of 10 min (https://www.nhi.gov.tw). Cancer type was divided into 14 categories according to the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) codes for each cancer type (Appendix Table 1). The categorization of cancer types also followed previous Taiwan Cancer registry evaluation report12. We used the Charlson comorbidity index (CCI) to assess the underlying medical condition of patients and calculated the CCI using NHI claims data in medical records with dates within the 1 year prior to cohort entry13. When calculating the CCI of the patients with stage-IV cancer, the cancer-related score and component were not included (cancer-free CCI). Socioeconomic status was determined by income reported for NHI premium calculation, which was divided into low income (receiving government subsidies due to being below the lowest living index and being exempt from NHI premiums and copayment), ≤ Q1, Q1–Q3, and > Q3, as previously detailed14.

Primary disease diagnosis was retrieved through the major in-patient diagnosis record of index hospitalisation. The diagnosis codes for categorising the primary disease diagnoses are summarised in Appendix Table 2.

Statistical analysis. Proportions or means were used to describe the demographic and clinical characteristics of the patients. The standardised difference was used to compare continuous and categorical variables at baseline before the index hospitalisation. The primary outcome was post-discharge survival, which was defined as the interval between the date of discharge and date of death. The secondary outcome was in-hospital mortality. Participants were censored if they were still alive at end of the study period (December 31, 2014).

The stage-IV cancer group was 1:1 matched with a noncancer group—both groups receiving in-hospital CPR—by exactly matching (not propensity score matching) with age, sex, year of CPR, and CCI. Logistic regression was used to identify factors associated with in-hospital mortality. The proportional hazards regression model was applied to explore the factors associated with post-discharge survival. Variables included cancer categories, primary diagnosis for hospitalization, sex, age, CCI score, socioeconomic status, cardioversion, duration of CPR, interval between diagnosis and CPR, chemotherapy, radiotherapy and tyrosine kinase inhibitor. These variables were selected because they potentially had an impact on patient survival15,16.

All data analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA). A P of < 0.05 on a two-sided test or a standardised difference of > 0.1 was considered statistically significant.
Results

Patient identification. The result of the patient identification process is summarised in Fig. 1. For the study period, 3,446 stage-IV cancer patients receiving in-hospital CPR were included.

Demographic data. The clinical characteristics of the included patients with stage-IV cancer are summarised in Table 1. Among the 3,446 patients, the majority were male (n = 2,545, 73.9%). The most common specific cancer type was lung cancer (n = 1,102, 32.0%), followed by oral cancer (n = 325, 9.4%) and colon cancer (n = 238, 6.9%). The great majority of patients underwent anticancer therapy before they received CPR, with the therapies including chemotherapy (n = 2,173, 63.1%) and radiotherapy (n = 1,595, 46.3%). The mean interval between cancer diagnosis and CPR was 317.1 days (standard deviation [SD] = 388.3 days) and did not differ between the hospital survivors and nonsurvivors (standardised difference [STD] = 0.031).

The primary disease diagnosis of index hospitalisation was cancer related in the majority of patients (n = 2,325, 67.5%), followed by respiratory disease related (n = 476, 13.8%). During the CPR episode, 17.8% of the patients received cardioversion. CPR generally lasted 20–30 min (mean of 2.3 ± 1.7 in units of 10 min). Only 17.2% of patients (n = 592) survived the index hospitalisation.

Those who survived to discharge were more likely to have oral cancer, admission due to respiratory disease, shorter CPR duration, and higher CCI, but less likely to have stomach cancer.

The overall in-hospital mortality rate was 82.8% (n = 2,854), which increased to 87.5% (n = 2,996) if hospital survivors were defined as being alive 7 days after discharge. The in-hospital mortality rate by year and with two different definitions is illustrated in Appendix Fig. 1.

Factors associated with in-hospital mortality. Multivariable logistic regression revealed that stomach cancer (adjusted odds ratio [aOR] = 2.61, 95% confidence interval [CI] = 1.44–4.75), liver cancer (aOR = 1.79, 95% CI = 1.09–2.95), and longer CPR duration (aOR = 1.33, 95% CI = 1.24–1.43 per 10-min increment) were associated with higher in-hospital mortality rate, whereas oral cancer (aOR = 0.66, 95% CI = 0.44–0.99) was associated with lower in-hospital mortality rate. Furthermore, the proportion of in-hospital mortality and survival of individual cancer type with two definitions was described in Appendix Table 3.

Hospital survivors among stage-IV cancer patients receiving in-hospital CPR. Among the 592 hospital survivors, only a small proportion received further anticancer therapy (chemotherapy, n = 50, 8.5%; radiotherapy, n = 32, 5.4%; total, n = 60, 10.1%). The median post-discharge survival was 22 days. The survival curves of different cancer types are presented in Fig. 2a.

Factors associated with post-discharge survival. The risk factors associated with shorter post-discharge survival were stomach cancer (adjusted hazard ratio [aHR] = 3.21, 95% CI = 1.72–5.98), liver cancer (aHR = 2.34, 95% CI = 1.46–3.76), lung cancer (aHR = 1.78, 95% CI = 1.30–2.46), receipt of chemotherapy prior to CPR (aHR = 1.33, 95% CI = 1.09–1.63), CPR in 2014 (compared with that in 2009, aHR = 2.03, 95% CI = 1.41–2.91), and longer CPR duration (aHR = 1.15, 95% CI = 1.08–1.23 per 10-min increment). Patients who were admitted due to renal disease (aHR = 0.32, 95% CI = 0.11–0.92) and trauma (aHR = 0.30, 95% CI = 0.11–0.81) had better prognosis. The prognostic factors associated with in-hospital mortality and post-discharge survival are summarised in Table 2.

Matched cohorts of stage-IV cancer and noncancer patients receiving in-hospital CPR. A stage-IV cancer group and 1:1 age-, sex-, year of CPR-, and CCI–matched comparison group of noncancer
patients (Table 3) were selected (each with 3,425 patients; 21 stage-IV cancer patients could not be matched with noncancer patients). 589 cancer and 612 non-cancer patients survived to discharge (Appendix Table 4). The mortality rate was 82.8% (n = 2,836) and 82.1% (n = 2,813) in stage-IV cancer and noncancer cohorts, respectively.

|                         | Overall patients (n = 3,446) | Survived to discharge (n = 592) | Died during hospitalization (n = 2854) | STD |
|-------------------------|------------------------------|---------------------------------|--------------------------------------|-----|
| **Age (mean ± SD)**     | 64.1 ± 14.4                  | 65.0 ± 14.2                     | 64.0 ± 14.5                          | 0.074 |
| **Male**                | 2545 (73.9)                  | 442 (74.7)                      | 2103 (73.7)                          | 0.016 |
| **Socioeconomic status**|                              |                                 |                                      |     |
| Low income              | 150 (4.4)                    | 19 (3.2)                        | 131 (4.6)                            | 0.071 |
| ≤Q1                     | 1243 (36.1)                  | 208 (35.1)                      | 1035 (36.3)                          | 0.024 |
| Q1–Q3                   | 1332 (38.7)                  | 244 (41.2)                      | 1088 (38.1)                          | 0.063 |
| >Q3                     | 721 (20.9)                   | 121 (20.4)                      | 600 (21.0)                           | 0.014 |
| **Cancer type**         |                              |                                 |                                      |     |
| Oral Cavity             | 325 (9.4)                    | 75 (12.7)                       | 250 (8.8)                            | 0.127 |
| Oropharynx              | 177 (5.1)                    | 39 (6.6)                        | 138 (4.8)                            | 0.076 |
| Hypopharynx             | 174 (5.1)                    | 38 (6.4)                        | 136 (4.8)                            | 0.072 |
| Esophagus               | 163 (4.7)                    | 26 (4.4)                        | 137 (4.8)                            | 0.020 |
| Stomach                 | 194 (5.6)                    | 16 (2.7)                        | 178 (6.2)                            | 0.172 |
| Colon                   | 238 (6.9)                    | 43 (7.3)                        | 195 (6.8)                            | 0.017 |
| Rectum                  | 135 (3.9)                    | 27 (4.6)                        | 108 (3.8)                            | 0.039 |
| Liver                   | 237 (6.9)                    | 30 (5.1)                        | 207 (7.3)                            | 0.091 |
| Lung                    | 1102 (32.0)                  | 171 (28.9)                      | 931 (32.6)                           | 0.081 |
| Breast                  | 83 (2.4)                     | 16 (2.7)                        | 67 (2.4)                             | 0.023 |
| Cervix                  | 38 (1.1)                     | 8 (1.4)                         | 30 (1.1)                             | 0.028 |
| Prostate                | 170 (4.9)                    | 35 (5.9)                        | 135 (4.7)                            | 0.053 |
| Bladder                 | 49 (1.4)                     | 7 (1.2)                         | 42 (1.5)                             | 0.025 |
| Other                   | 361 (10.5)                   | 61 (16.9)                       | 300 (10.5)                           | 0.007 |
| **CPR year**            |                              |                                 |                                      |     |
| 2009                    | 579 (16.8)                   | 108 (18.2)                      | 471 (16.5)                           | 0.046 |
| 2010                    | 656 (19.0)                   | 117 (19.7)                      | 539 (18.9)                           | 0.022 |
| 2011                    | 655 (19.0)                   | 116 (19.6)                      | 539 (18.9)                           | 0.018 |
| 2012                    | 609 (17.7)                   | 108 (18.2)                      | 501 (17.6)                           | 0.018 |
| 2013                    | 568 (16.5)                   | 88 (14.9)                       | 480 (16.8)                           | 0.054 |
| 2014                    | 379 (11.0)                   | 55 (9.3)                        | 324 (11.4)                           | 0.068 |
| **CCI (mean ± SD)**     | 3.90 ± 2.20                  | 4.12 ± 2.31                     | 3.85 ± 2.17                          | 0.119 |
| **Anti-cancer therapy** |                              |                                 |                                      |     |
| Chemotherapy            | 2175 (63.1)                  | 361 (70.0)                      | 1814 (63.6)                          | 0.053 |
| Radiotherapy            | 1595 (46.5)                  | 285 (48.1)                      | 1310 (45.9)                          | 0.045 |
| TKI                     | 316 (9.2)                    | 52 (8.8)                        | 264 (9.3)                            | 0.016 |
| **Interval between cancer diagnosis and index admission (mean ± SD)** | 317.1 ± 388.3 | 327.1 ± 395.8 | 315.0 ± 386.8 | 0.031 |
| **Primary disease for admission** |                        |                                 |                                      |     |
| Cancer-related          | 2325 (67.5)                  | 380 (64.2)                      | 1945 (68.2)                          | 0.082 |
| Cardiovascular          | 117 (3.4)                    | 22 (3.7)                        | 95 (3.3)                             | 0.021 |
| Gastrointestinal        | 77 (2.2)                     | 8 (1.4)                         | 69 (2.4)                             | 0.078 |
| Neurologic              | 20 (0.6)                     | 7 (1.2)                         | 13 (0.5)                             | 0.081 |
| Renal                   | 19 (0.6)                     | 4 (0.7)                         | 15 (0.5)                             | 0.019 |
| Respiratory             | 476 (13.8)                   | 100 (16.9)                      | 376 (13.2)                           | 0.104 |
| Sepsis                  | 23 (0.7)                     | 3 (0.5)                         | 20 (0.7)                             | 0.025 |
| Trauma                  | 17 (0.5)                     | 5 (0.8)                         | 12 (0.4)                             | 0.054 |
| Other                   | 372 (10.8)                   | 63 (10.6)                       | 309 (10.8)                           | 0.006 |
| Receiving cardioversion| 613 (17.8)                   | 114 (19.3)                      | 499 (17.5)                           | 0.046 |
| **CPR duration (minutes)** | 23 ± 17                     | 17 ± 13                         | 24 ± 18                              | 0.409 |

Table 1. Clinical characteristics of Stage IV cancer patients who received in-hospital CPR. Note: CCI, Charlson comorbidity index; CPR, cardiopulmonary resuscitation; SD, standard deviation; STD, standardized difference; TKI, tyrosine kinase inhibitor. Data are number (%) unless otherwise mentioned. Percentages in the three columns are for the column and not the row.
Logistic regression revealed that no association between noncancer and stage-IV cancer cohorts and in-hospital mortality. Proportional hazard ratio analysis revealed that the patients with stage-IV cancer had shorter post-discharge survival \((aHR = 1.28, 95\% CI = 1.08–1.50)\) than the noncancer patients. The post-discharge survival curves of the matched noncancer and stage-IV cancer groups are presented in Fig. 2b.

### Table 2. Independent prognostic factors of in-hospital mortality and post-discharge survival.

|                           | In-hospital mortality (logistic regression) | Post-discharge survival (proportional hazards regression) |
|---------------------------|--------------------------------------------|----------------------------------------------------------|
|                           | Adjusted OR* | 95% CI | P value | Adjusted HR* | 95% CI | P value |
| CPR year in 2014 (compared with 2009) | 1.47       | 1.01–2.16 | 0.129 | 2.03       | 1.41–2.91 | <0.001 |
| Stomach cancer            | 2.61       | 1.44–4.75 | 0.002 | 3.21       | 1.72–5.98 | <0.001 |
| Liver cancer              | 1.79       | 1.09–2.95 | 0.022 | 2.34       | 1.46–3.76 | <0.001 |
| Lung cancer               | 1.35       | 0.95–1.92 | 0.096 | 1.78       | 1.30–2.46 | <0.001 |
| Oral cancer               | 0.66       | 0.44–0.99 | 0.043 | 0.81       | 0.56–1.15 | 0.239 |
| CCI                       | 0.93       | 0.87–0.99 | 0.023 | 0.94       | 0.88–1.00 | 0.062 |
| CPR duration (every ten minutes) | 1.33                  | 1.24–1.43 | <0.001 | 1.15       | 1.08–1.23 | <0.001 |
| Chemotherapy prior to CPR | 1.10       | 0.88–1.36 | 0.404 | 1.33       | 1.09–1.63 | 0.004 |
| Admission for renal disease | 0.66       | 0.21–2.12 | 0.485 | 0.32       | 0.11–0.92 | 0.034 |
| Admission for trauma disease | 0.50       | 0.17–1.50 | 0.214 | 0.30       | 0.11–0.81 | 0.018 |

Note: CCI, Charlson comorbidity index; CI, confidence interval; CPR, cardiopulmonary resuscitation; HR, hazard ratio; OR, odds ratio. *Variables in the model included year of CPR, cancer types, primary disease for admission, gender, age, socioeconomic status, cardioversion, radiotherapy prior to CPR, chemotherapy prior to CPR, and cancer diagnosis to CPR.

STD = 0.039, p = 0.46. Logistic regression revealed that no association between noncancer and stage-IV cancer cohorts and in-hospital mortality. Proportional hazard ratio analysis revealed that the patients with stage-IV cancer had shorter post-discharge survival \((aHR = 1.28, 95\% CI = 1.08–1.50)\) than the noncancer patients. The post-discharge survival curves of the matched noncancer and stage-IV cancer groups are presented in Fig. 2b.
Discussion

We have noted that patients with stage-IV cancer who received CPR had poor prognosis, with lung, liver, or stomach cancer patients having even poorer outcomes. The median survival after discharge was less than 1 month, and few survivors received subsequent anticancer treatment after their CPR event. Although the in-hospital mortality rates of the stage-IV cancer and noncancer cohorts were similar, the post-discharge survival among the patients with stage-IV cancer and receiving in-hospital CPR was inferior to that of the non-cancer patients receiving CPR. Thus, the decision of whether to perform CPR on those with advanced cancer must be carefully justified.

In Taiwan, end-stage cancer patients will receive CPR if no DNR orders has been signed\textsuperscript{17}. Discussing CPR issues—widely considered mandatory in the care of patients with late-stage cancer—can be difficult and challenging. Taiwan has an Eastern culture, in which talking about death is taboo\textsuperscript{18}. In addition, family caregivers are more frequently involved in decision-making than in Western countries\textsuperscript{17}. Inadequate discussion and disagreement between patients and caregivers, however, are common in Taiwan\textsuperscript{19}. In one study conducted in Taiwan, DNR orders were almost twice more likely to be signed by surrogates than by patients; a DNR order signed by the patient was associated with higher quality of end of life care\textsuperscript{20}. Breaking these communication barriers to achieve better patient care is therefore vital. Strategies such as promoting cultural change to make care more patient-centred, establishing standards for DNR discussions, and improving physician communication skills have been proposed for achieving superior patient care\textsuperscript{21}. Our study offers a key message to family caregivers, patients, and physicians in-charge that under most circumstances, refusing to sign a DNR and declining palliative care in late-stage cancer when experiencing cardiac arrest can lead to patient suffering.

Studies on CPR in patients with advanced cancer have reported a 5.6%–15% CPR success rate\textsuperscript{4,22,23}. Our study reported a 17.2% in-hospital survival rate and 12.5% survival rate at 7 days post-discharge. While there was no data regarding proportion of patients who underwent withdrawal of life-sustaining treatment post CPR, survival rate may be affected by characteristics of medical care system. The Taiwan NHI is known for its low-cost and comprehensive coverage\textsuperscript{24,25}. For instance, patients undergoing prolonged mechanical ventilation (intubation for more than 2 months) can reside in long-term respiratory care facilities under NHI coverage, regardless of
underlying disease status and projected survival\textsuperscript{18}. For patient families and caregivers, access to medical and nursing care with low financial burden leads to an aggressive attitude towards maintaining patients’ lives\textsuperscript{17}.

A Taiwanese study, conducted using a random sample from 5% of the overall population sample in the NHI database, also investigated the outcome of patients receiving CPR between 1997 and 2004\textsuperscript{28}. The study reported an overall 11.6% CPR success rate, as defined by surviving to discharge\textsuperscript{28}. Comparing with this previous study, our methodology was different\textsuperscript{28}. We targeted stage-IV cancer (staging would be unknown without linkage to the cancer registry), linked mortality statistics for definite death date, used whole population dataset and investigated the post-discharge outcome among hospital survivors. Furthermore, we used procedure codes rather than diagnosis codes to identify CPR episodes\textsuperscript{28}.

CPR in patients with advanced cancer may extend beyond hospital survival. Survival after discharge is a crucial outcome measure. Furthermore, oncologists should be concerned about whether those who survive until discharge can tolerate or receive further anticancer treatment. Most studies have failed to address these two critical questions\textsuperscript{6,29,30}. Here, we found that only approximately 10% of hospital survivors received further anticancer therapy. Intolerance to subsequent anticancer therapy may reflect the devastating nature of cardiac arrest events. Deterioration of neurological function and organ damage possibly precludes the receipt of anticancer therapy\textsuperscript{41,42}. If the decision to perform CPR is based on the expectation that further anticancer therapy will be administered, our results suggest that this goal is unachievable in the vast majority of patients.

Our study also revealed that cancer type was an essential prognostic factor for cancer patients who experience cardiac arrest. This may be unsurprising given that the outcome and survival of different cancer types vary, regardless of CPR events\textsuperscript{43}. For instance, lung cancer is the leading cause of cancer-related death worldwide, and patients with advanced lung cancer generally have poor prognosis\textsuperscript{44}. The treatment options for nonresectable advanced hepatocellular carcinoma are limited\textsuperscript{45}. In Taiwan, oral cancer had the highest stage-specific survival, whereas liver cancer had the lowest\textsuperscript{36}. Therefore, the presence of advanced cancer and specific cancer type should be considered when discussing CPR decisions with patients and their families.

Some other findings of our study are also of interest. Pre-CPR chemotherapy was associated with shorter post-discharge survival in our study. This may indicate that patients who have previously undergone chemotherapy have less available treatment options if they survived their CPR episode or were in poorer general condition compared with those untreated. In addition, CCI appears to be a favourable prognostic factor for in-hospital mortality. The patients with higher CCI were more likely to receive CPR due to an underlying comorbidity, which can be readily treated, rather than cancer-related complications. This survival benefit, however, was not detected in the post-discharge survival analysis.

Our study included a matched comparison group of noncancer patients, which was uncommon in previous studies\textsuperscript{23,32}. The creation of matched comparison cohort of non-cancer patients, however, was not intended to provide a direct comparison of the outcome of cancer and non-cancer patients receiving CPR. These two groups were still different in their primary diagnosis for admission and CPR-related characteristics (Table 3). Rather, we aimed to provide more information to help facilitate decision-making for stage IV cancer patients while CPR for non-cancer patients was more frequently encountered and experienced in clinical practice. Interestingly, despite an approximate one month difference in median survival between cancer and non-cancer patients, there was a long tail of survival curve among both groups. This highlights the fact that for non-cancer patients who experienced CPR events, some may achieve remarkable long-term survival. This was also the case for stage IV cancer patients. Certain cancer types with favorable prognostic factors, such as lung adenocarcinoma with tyrosine kinase inhibitor (TKI)-sensitive epidermal growth factor receptor (EGFR) mutation or hormone receptor-positive breast cancer, may achieve long-term survival once they survived the CPR events\textsuperscript{37,38}.

One, however, needs to avoid simply interpreting the results of our study to be that CPR in cancer patients is futile. While survival rate of less than 1% is commonly regarded as the threshold of medical futility\textsuperscript{39,40} and the in-hospital mortality rate was 17.2% in our study. Furthermore, a recent review also addressed that physicians should avoid withdrawal of care in the absence of definite prognostic signs either during or after cardiac arrest\textsuperscript{41}. Our study intended to describe the general outcome of advanced cancer patients receiving CPR and thus provided information that could help decision-making. Individual patient evaluation and discussion are still irreplaceable.

Our study has some limitations. First, we could not collect performance status and neurological statuses, both of which are crucial components for understanding prognosis and thus prerequisites for decision-making regarding CPR\textsuperscript{42,43}. This may be a direction for future investigations. Second, we could not identify the cause of CPR from the claims database. Nonetheless, we detected no difference between groups with different primary diagnoses at admission.

**Conclusion**

Our nationwide population-based study revealed that advanced cancer patients receiving CPR had a poor prognosis, with those having lung, liver, or stomach cancer having even poorer outcome. Even among the hospital survivors, only a small minority went on to receive further anticancer therapy. Given the high in-hospital mortality rate and short survival time among the hospital survivors, strong indications of a high likelihood of survival (e.g. using the most highly effective and tolerable anticancer treatment available) are required to justify the decision to perform CPR on patients with advanced cancer.

**Data Availability**

All data were deposited in the national health insurance databases located in the Ministry of Health and Welfare, Taiwan and were not available for sharing without permission.
References
1. Champignonelle, B., Cariou, A. & Vincent, F. (2016) Cardiopulmonary Resuscitation and Benefit to Patients With Metastatic Cancer. JAMA. Intern. Med. 176, 142 (2016).
2. Nabozny, M. J., Steffens, N. M. & Schwarze, M. L. When Do Not Resuscitate Is a Nonchoice Choice: A Teachable Moment. JAMA. Intern. Med. 175, 1444–1445 (2015).
3. Varon, J. et al. Should a cancer patient be resuscitated following an in-hospital cardiac arrest? Resuscitation. 36, 165–168 (1998).
4. Reisfield, G. M. et al. Survival in cancer patients undergoing in-hospital cardiopulmonary resuscitation: a meta-analysis. Resuscitation. 71, 152–160 (2006).
5. Champignonelle, B. et al. What is the outcome of cancer patients admitted to the ICU after cardiac arrest? Results from a multicenter study. Resuscitation. 92, 38–44 (2015).
6. Khasawneh, F. A., Kamel, M. T. & Abu-Zaid, M. I. Predictors of cardiopulmonary arrest outcome in a comprehensive cancer center intensive care unit. Scand. J. Trauma. Resusc. Emerg. Med. 21, 18 (2013).
7. Osiński, A. et al. Do-not-resuscitate orders in cancer patients: a review of literature. Support. Care. Cancer. 25, 677–685 (2017).
8. Wang, J. Y. et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months. Chest. 147, 520–528 (2015).
9. Lee, M. R. et al. Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan. Eur. Respir. J. 50 (2017).
10. Chang, L. Y. et al. Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study. BMC. Infect. Dis. 18, 64 (2018).
11. Chiang, C. J. et al. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Ipn. J. Clin. Oncol. 45, 291–296 (2015).
12. Taiwan Cancer Registry Database 2011 Analysis Report, http://tcr.cph.ntu.edu.tw/uploadimages/CA15_LF100_20140415.pdf (2014).
13. Quan, H. et al. Coding algorithms for defining Comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care. 43, 1130–1139 (2005).
14. Hsu, C. C. et al. Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage. Diabetes. Care. 35, 2286–2292 (2012).
15. Xu, L. et al. Factors associated with overall survival in 1702 patients with nasopharyngeal carcinoma: Significance of intensive neoadjuvant chemotherapy and radiation break. Radiother. Oncol. 96, 94–99 (2010).
16. Huang, H. L. et al. Factors associated with lung cancer patients refusing treatment and their survival: a national cohort study under a universal health insurance in Taiwan. PLoS. One. 9, e101731 (2014).
17. Wen, K. Y. et al. Insights into Chinese perspectives on do-not-resuscitate (DNR) orders from an examination of DNR order form completeness for cancer patients. Support. Care. Cancer. 21, 2593–2598 (2013).
18. Kim, S., Hahn, K. H., Park, H. W., Kang, H. H. & Sohn, M. A. Korean perspective on developing a global policy for advance directives. Bioethics. 24, 113–117 (2010).
19. Liu, T. W. et al. Terminally Ill Taiwanese Cancer Patients’ and Family Caregivers’ Agreement on Patterns of Life-Sustaining Treatment Preferences Is Poor to Fair and Declines Over a Decade: Results From Two Independent Cross-Sectional Studies. J. Pain. Symptom. Manage. 54, 35–45 (2017).
20. Liang, Y. H. et al. Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. Support. Care. Cancer. 25, 533–539 (2017).
21. Yuen, J. K., Reid, M. C. & Fetter, M. D. Hospital do-not-resuscitate orders: why they have failed and how to fix them. J. Gen. Intern. Med. 26, 791–797 (2011).
22. Taran, A. et al. Cardiopulmonary resuscitation inpatient outcomes in cancer patients in a large community hospital. Del. Med. J. 84, 117–121 (2012).
23. Bruckel, J. T. et al. Patterns of Resuscitation Care and Survival After In-Hospital Cardiac Arrest in Patients With Advanced Cancer. J. Oncol. Pract. 13, e821–e830 (2017).
24. Ho, C. W. S. Taiwan’s healthcare report 2010. EPMA. J. 1, 563–585 (2010).
25. Wu, T. Y., Majed, A. & Kuo, K. N. An overview of the healthcare system in Taiwan. London. J. Prim. Care. 3, 115–119 (2010).
26. Lee, M. R. et al. Acquisition of Mycobacterium abscessus among ventilator-dependent patients in Taiwan chronic respiratory care facilities. Future. Microbiol. 11, 491–500 (2016).
27. Tang, S. T. et al. Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J. Clin. Oncol. 27, 4613–4618 (2009).
28. Lin, M. H. et al. Cardiopulmonary resuscitation for hospital inpatients in Taiwan: an 8-year nationwide survey. Resuscitation. 83, 343–346 (2012).
29. Zafar, W. et al. Outcomes of In-Hospital Cardiopulmonary Resuscitation Among Patients With Cancer. Am. J. Hosp. Palliat. Care. 34, 212–216 (2017).
30. Miller, A. H. et al. Cardiopulmonary resuscitation outcomes in a cancer center emergency department. SpringerPlus. 4, 106 (2015).
31. Koenig, M. A. Brain resuscitation and prognosis after cardiac arrest. Crit. Care. Clin. 30, 765–783 (2014).
32. Nolan, J. P. et al. Incidence and outcome of in-hospital cardiac arrest in the United Kingdom National Cardiac Arrest Audit. Resuscitation. 85, 987–992 (2014).
33. Kjøstad, O. J. & Haugen, D. F. Cardiopulmonary resuscitation in palliative care cancer patients. Tidsskr. Nor. Laegeforen. 133, 417–421 (2013).
34. Hirsch, F. R. et al. Lung cancer: current therapies and new targeted treatments. Lancet. 389, 299–311 (2017).
35. Sun, W. & Cabrera, R. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. J. Gastrointest. Oncol. 49, 107–115 (2018).
36. Chiang, C. J. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. J. Formos. Med. Assoc. 115, 1076–1088 (2016).
37. Okamoto, I. et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung. Cancer. 117, 14–19 (2018).
38. Chen, L. et al. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast. Cancer. Res. Treat. 147, 609–616 (2014).
39. Morrison, L. J. et al. Part 3: ethics: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 122, 5665–5675 (2010).
40. Schneiderman, L. J. et al. Medical futility: its meaning and ethical implications. Ann. Intern. Med. 112, 949–954 (1990).
41. Andersen, L. W. et al. In-Hospital Cardiac Arrest: A Review. JAMA. 321, 1200–1210 (2019).
42. Tang, S. T. et al. Associations between accurate prognostic understanding and end-of-life care preferences and its correlates among Taiwanese terminally ill cancer patients surveyed in 2011–2012. Psychonoscol. 23, 780–787 (2014).
43. Ebell, M. H. et al. Development and validation of the Good Outcome Following Attempted Resuscitation (GO-FAR) score to predict neurologically intact survival after in-hospital cardiopulmonary resuscitation. JAMA. Intern. Med. 173, 1872–1878 (2013).
Acknowledgements
We thank statistician Jun-Fu Zhang for help in statistic analysis and checking basic data. This manuscript was edited by Wallace Academic Editing. This study was funded by National Taiwan University Hospital Hsin-Chu Branch (106-HCH022), Taiwan Ministry of Science and Technology (MOST104-2321-B-002-058), and Ministry of Health and Welfare (MOHW105-CDC-C-114-00103). The funders had no role in the study design, data analysis, and manuscript writing.

Author Contributions
M.R.L., J.C.K. and J.Y.W. designed the study and analysed the data. M.R.L., K.L.Y., H.Y.K., T.H.L. and J.S.T. drafted the manuscript. M.R.L., K.L.Y. and T.H.L. prepared the figures. All authors have read and approved the final version of the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45977-4.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019